Do you favor switching a virologically suppressed patient with HIV and significant weight gain to dolutegravir/lamivudine over bictegravir/emtricitabine/tenofovir alafenamide, given PASO-DOBLE trial data showing noninferior virologic efficacy with less weight gain?

I wouldn’t “favor” DTG/3TC over BIC/FTC/TAF purely on the basis of PASO-DOBLE’s average weight trajectory, because the weight effect size is modest, the trial is not designed to prove superiority on metabolic outcomes, and regimen choice in a suppressed patient hinges on a few high-impact individual...